GlobeNewswire Inc.··Rosen Law FirmDisc Medicine Stock Plunges 22% After FDA Rejection; Class Action Investigation Underway
Disc Medicine ($IRON) shares tumbled 22% following FDA rejection of its bitopertin program. Law firm investigates potential securities violations and shareholder losses.
IRONNUAINUAIWIMMPinvestor lossessecurities class action